Halozyme Therapeutics, Inc. (HALO) — Stock Price, Chart & Analysis
Halozyme Therapeutics, Inc. (HALO) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $13.07B and a trailing P/E ratio of 32.71. Over the past 52 weeks, HALO has traded between $61.23 and $115.18. Halozyme Therapeutics, Inc. does not currently pay a regular dividend. View the live HALO chart, technical opinion, analyst ratings, fundamentals and latest news below.
Halozyme Therapeutics, Inc. (HALO) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $13.07B |
| P/E ratio (TTM) | 32.71 |
| EPS (TTM) | $3.52 |
| 52-week high | $115.18 |
| 52-week low | $61.23 |
| Beta | 0.88 |
| Avg. volume | 2.07M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Halozyme Therapeutics, Inc. (HALO)
How much does one share of Halozyme Therapeutics, Inc. cost?
As of the latest update, one share of Halozyme Therapeutics, Inc. (HALO) trades at $100 (+0.00% today).
What is Halozyme Therapeutics, Inc.'s market cap?
Halozyme Therapeutics, Inc. has a market capitalization of approximately $13.07B.
What is Halozyme Therapeutics, Inc.'s P/E ratio?
Halozyme Therapeutics, Inc. has a trailing price-to-earnings (P/E) ratio of 32.71.
What is Halozyme Therapeutics, Inc.'s earnings per share (EPS)?
Halozyme Therapeutics, Inc.'s trailing twelve-month EPS is $3.52.
Does Halozyme Therapeutics, Inc. pay a dividend?
Halozyme Therapeutics, Inc. does not currently pay a regular dividend.
What is Halozyme Therapeutics, Inc.'s 52-week trading range?
Over the past year, HALO has traded between $61.23 and $115.18.
What is the analyst price target for Halozyme Therapeutics, Inc.?
The mean analyst price target for Halozyme Therapeutics, Inc. is $99.56. This is informational only and not investment advice.
Latest Halozyme Therapeutics, Inc. (HALO) news
- Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?News · Sep 23, 2026
- Halozyme (HALO) Just Made A $1.3B Bet On ItselfNews · Sep 22, 2026
- Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?News · Sep 21, 2026
- Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033News · Sep 18, 2026
- Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033News · Sep 16, 2026
- Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in FocusNews · Sep 2, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live HALO dashboard…